fibrosis

Recursion Pharmaceuticals Inc (NASDAQ: RXRX) expanded its existing strategic collaboration in fibrosis with Bayer AG (OTC: BAYRY).  The expanded collaboration will include Recursion's inferential search capabilities based on its growing maps of human cellular...

Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) has announced histology and biomarkers analysis results from the Ongoing Open-Label Part of the ARMOR Phase 3 study of Aramchol in NASH and liver fibrosis stage 1 3 patients.  Galmed previously announced a substantial effect on ...

Angion Biomedica Corp (NASDAQ: ANGN) has announced positive results from its Phase 1 study in healthy volunteers for ANG-3070 for fibrotic diseases.  In the 97-volunteer trial, ANG-3070 achieved drug exposures in humans exceeding exposures in which activity was demonstrated in...

Amid the continued evolution of the COVID-19 landscape, Galecto Inc (NASDAQ: GLTO) said it would focus on the Phase 2 pipeline of fibrosis and cancer treatments, despite announcing positive preliminary topline results from an investigator-initiated trial examining GB0139 in...

Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) has announced licensing deals for two new monoclonal antibodies (mAbs), CRB-601 and CRB-602, that target integrins to inhibit activation of transforming growth factor β (TGFβ). TGFβ is a multifunctional cytokine...

Based on interim pharmacokinetics (PK) results from the ongoing multiple ascending dose study Liminal BioSciences Inc (NASDAQ: LMNL) has decided not to move fezagepras into a Phase 2 study in Idiopathic Pulmonary Fibrosis and a Phase 1a/2b study in Hypertriglyceridemia. The Company...

Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) has announced positive interim 48-week liver biopsy results from the Phase 2 AROAAT2002 study evaluating ARO-AAT for rare genetic liver disease associated with alpha-1 antitrypsin deficiency (AATD). AATD is the lack of a...